Drug Trial Radar · NCT06437639
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Sep 15, 2023
Primary completion
Nov 29, 2023
Study completion Feb 2, 2024
Sponsor
- Lead sponsor
- PharmasoftIndustry
- Sponsor type
- Industry
- First posted
- May 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.
Conditions
- Primary Open-Angle Glaucoma (POAG)
Interventions
MexidolDrug
Neurocytoprotector
Primary outcomes
What the sponsor says the trial is designed to measure.
- Degree of expression of mitochondrial dysfunctionTime frame: 90 days
- Dynamics of the structural and functional characteristics of mitochondriaTime frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tyumen Scientific Center of the Russian Academy of Sciences
Tyumen, Russian Federation, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.